Back to today’s briefing

Story perspectives

CG Oncology Appoints Jim DeTore as CFO, Boosts Leadership Stability

4/14/2026

42 4 Full Breakdown

Summary

Story summary

CG Oncology, Inc. named Jim DeTore Chief Financial Officer on April 13, 2026.
DeTore previously served as Interim Principal Financial and Accounting Officer and will report to the CEO.
He will receive a $500,000 base salary, a 45% bonus, $4 million in stock options, and $1 million in performance stock units tied to the launch.
The appointment may signal leadership stability and influence CG Oncology's share price.

1 of 1

Story summary

CG Oncology, Inc. named Jim DeTore Chief Financial Officer on April 13, 2026.
DeTore previously served as Interim Principal Financial and Accounting Officer and will report to the CEO.
He will receive a $500,000 base salary, a 45% bonus, $4 million in stock options, and $1 million in performance stock units tied to the launch.
The appointment may signal leadership stability and influence CG Oncology's share price.